MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Catalyst Pharmaceuticals Market Cap 2011-2026 | CPRX
As of February 11, 2026 Catalyst Pharmaceuticals has a market cap of $ 2.78 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Catalyst Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.44 B | 1.56 B | 1.48 B | 595 M | 377 M | 431 M | 254 M | 299 M | 90.3 M | 150 M | 234 M | 90.5 M | 16.2 M | 23.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.44 B | 16.2 M | 574 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M |  USA |
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amarin Corporation plc
AMRN
|
440 M | $ 14.58 | -2.93 % | $ 5.94 B |  Irlanda |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 0.82 | -2.71 % | $ 4.47 M |  China |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M |  Canada |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M | China |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
87.8 M | $ 2.99 | 0.17 % | $ 168 M | China |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.48 | -0.78 % | $ 8.37 B |  Australia |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Athira Pharma
ATHA
|
16.2 M | - | - | $ 269 M | USA |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 9.14 | -1.14 % | $ 1.47 B | Britain |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 217.62 | -2.93 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Codexis
CDXS
|
291 M | $ 1.2 | -4.4 % | $ 88.1 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
5.65 B | - | -6.81 % | $ 3.04 B | USA |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aridis Pharmaceuticals
ARDS
|
4.13 M | - | 17.91 % | $ 11.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 108.91 | -0.02 % | $ 27.2 B | Germany |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
Cabaletta Bio
CABA
|
20.5 M | $ 2.54 | -2.38 % | $ 2.97 M | USA |
 |
Calithera Biosciences
CALA
|
960 M | - | -10.95 % | $ 876 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.4 | -2.45 % | $ 357 M | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
1.83 B | $ 14.71 | -0.34 % | $ 4.55 B | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 4.28 | -1.34 % | $ 9.31 B |  Israel |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |